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Abstract 
Rationale: Pulmonary infection and malnutrition in cystic fibrosis are associated with decreased 
survival. Glutamine has a possible anti-microbial effect, with a specific impact against 
Pseudomonas aeruginosa. We aimed to test the hypothesis that oral glutamine supplementation 
(21g/day) for eight weeks in adults with cystic fibrosis would decrease pulmonary inflammation 
and improve clinical status. Methods: The study design was a randomised double-blind placebo-
controlled study design with an iso-nitrogenous placebo. The primary analysis was intention to 
treat, and the primary outcome was change in induced sputum neutrophils. Results: 39 individuals 
were recruited and 36 completed the study. Glutamine supplementation had no impact on any of 
the outcome measures in the intention-to-treat analysis. In the per protocol analysis, glutamine 
supplementation was associated with an increase in induced sputum neutrophils (p=0.046), total 
cells (p=0.03), and in Pseudomonas isolation agar colony forming units (p=0.04) compared to 
placebo. Conclusions: There was no effect of glutamine supplementation on markers of pulmonary 
inflammation in the intention-to-treat analysis. 
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Introduction 
Cystic fibrosis (CF) is a disease characterised by chronic pulmonary infections and impaired 
nutrition 1. In recent decades, new interventions have been developed and these collectively have 
resulted in large improvements in survival over this period 2. However, the median age at death in 
2008 was approximately 27 years 3, and further interventions are required to build on the current 
knowledge and hence enable individuals with CF to live longer. These interventions should ideally 
be easily deliverable in the home, reducing the need for recurrent hospital visits. 
 
Glutamine is an amino acid that may be clinically active against infection. In an early randomised 
controlled trial of acute trauma patients 4, those allocated to parenteral glutamine had a large 
reduction in secondary infections, including pneumonia and sepsis. Clinical benefits have also 
been reported after glutamine supplementation in a recent meta-analysis of the studies in critically 
ill and surgical patients, with a significant decrease in infections 5. The biological mechanism of 
any anti-microbial effect is unclear, although a model of skin burns in animals demonstrated a 
large reduction in infection with Pseudomonas aeruginosa 6, suggesting a possible specific activity 
against this bacterium that may also explain some of the clinical benefits seen in patients with 
severe burns 7,8. More generally, phagocytosis is impaired in the context of protein-energy 
malnutrition, possibly as a consequence of decreased complement levels 9. 
 
Individuals with CF often have a low lean body mass and this is associated with increased 
subsequent mortality 10. The disease is also characterised by chronic infection with Pseudomonas 
aeruginosa, which is an independent indicator of accelerated decline in lung function 11 and 
decreased survival 12. Children with CF have lower intracellular glutamine levels in their 
neutrophils than controls, which may modify their ability to mount an effective response to infection 
13, as neutrophils are an important component in protecting the healthy lungs from infection 14. We 
hypothesised that supplementation with glutamine may thus have clinical benefits to individuals 
with CF and completed a randomised double-blind placebo-controlled trial to test this using 
sputum biomarkers of inflammation as the main outcome measure 15. 
 
Materials and methods 
The study used a randomised double-blind parallel group trial design. The study was registered as 
a clinical trial (EudraCT2007-006204; ISRCTN22534872) and approved by the Nottingham 
Research Ethics Committee. Informed consent was obtained from all participants. 
 
Study population 
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We recruited participants from Nottingham University Hospitals NHS Trust and Birmingham 
Heartlands Hospital Heart of England NHS Trust. The inclusion criteria were: diagnosis of CF 
based on genotype and/or positive sweat test, forced expiratory volume in one second (FEV1) of 
25%-80% predicted and chronic pulmonary Pseudomonas aeruginosa infection with a positive 
isolation of Pseudomonas aeruginosa from the airways in the previous 12 months. Individuals 
were excluded if they were pregnant or breastfeeding, had a pulmonary exacerbation or change in 
pulmonary therapy in the preceding 4 weeks, had received a lung transplant, had poorly controlled 
diabetes mellitus, liver failure, had a liver function assay greater than three times the upper limit of 
normal or were involved in another interventional clinical trial. 
 
Randomisation and intervention 
The randomisation schedule was generated using STATA (Texas, USA) stratified for centre and 
used variable block sizes. The randomisation schedule was held in pharmacy in Nottingham and 
both researchers and participants were blinded to allocation throughout the study. Participants 
were randomised to receive either 21g L-glutamine daily (one sachet of 7g glutamine powder to be 
dissolved in water and taken three times a day, Essential Nutrition, Brough, UK) or a matched iso-
nitrogenous placebo (a mixture of 82% asparagine and 18% glycine) in identical sachets for an 8-
week period. The dose of glutamine was pragmatically chosen as being consistent with the dose 
that appeared both biologically active based on the literature available at the time of study and a 
tolerable size to facilitate adherence by the patients. 
 
Data Collection 
Prospective participants were seen at a screening visit and for three further visits. Firstly, before 
starting the intervention/placebo and then at week 4 (+/-7 days) and week 8 (+/-7days). 
Participants were then reviewed by telephone call one month after completing the study to ensure 
there were no deferred consequences of participation in the study. 
 
We collected baseline demographic and clinical data before randomisation: weight, height, 
spirometry (FEV1, forced vital capacity (FVC), peak expiratory flow (PEF)). Based upon 
examination findings and symptoms, a composite clinical score as described by Jensen et al 16 
was calculated. Participants also completed the Cystic Fibrosis Questionnaire-Revised (CFQ-R), a 
validated quality of life questionnaire 17. This has 11 domain scores from 0-100, with higher scores 
representing a perception of greater well-being. 
 
Laboratory measurements 
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Induced sputum sample collection and processing were performed as previously described 18. 
Briefly, sputum plugs were selected and mixed with 4x weight/volume 0.1% dithiothreitol (DTT) 
and an equal volume of Dulbecco’s phosphate-buffered saline (PBS).  Samples were  filtered and 
assessed for cell viability and  differential cell counts were performed using Rappi Diff II. Colony 
forming unit (CFU) counts were performed on blood and Pseudomonas Isolation Agar using serial 
dilution with 0.9% saline, counted at 24hrs and 48hrs. Multiplex cytokine analyses for TNF- , IL-8, 
IL-6 and IL-  performed using a Bio-plex® (BioRad) using an 8-point standard curve and 
the average of samples run in duplicate. 
 
Statistical analysis 
Analysis of changes in measurements used student's t-tests and Wilcoxon rank sum tests as 
appropriate. The intention to treat analysis replaced any missing values with baseline values as 
part of the statistical analysis plan. Secondary analysis used per protocol analysis of all available 
paired data. The primary outcome measure was the change in induced sputum neutrophil count 
over eight weeks and the other measures were assessed as secondary outcomes. 
 
With 36 individuals providing data, the study would have over 80% power to detect an absolute  
75% reduction in sputum neutrophil count using data from Ordonez et al 19. All statistical analyses 
were performed using STATA SE 13.0 (Stata Corporation, Texas) software. 
 
 
Results 
489 patients were screened, and of these 180 patients were approached with 39 individuals being 
randomized into the study and 36 attending for the final visit (Figure 1). 24 (62%) were male, the 
mean age was 30 years and the mean percent predicted FEV1 was 47% (Table 1), with a value of 
41% in the glutamine supplementation group and 53% in the placebo group. 
 
In the intention-to-treat analysis, there was no difference between those who received glutamine 
supplementation compared to placebo for either the clinical measurements or the markers of 
pulmonary inflammation (p>0.05 for all values). In the per protocol analysis, supplementation with 
oral glutamine was associated with an increase in sputum neutrophils (p=0.046), total cells 
(p=0.03) and Pseudomonas Isolation Agar CFUs (p=0.04) compared to those who received 
placebo (Table 2). There was no change in any of the quality of life measurements in these paired 
data (data not presented). 
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Questioning of 30 participants at the end of the study assessed effective blinding of the study. 13 
were unsure, 12 thought they were receiving glutamine (8 correct), 5 thought they were not (4 
correct). There were no adverse events or side effects of treatment or placebo detected in the 
study. 
 
 
Discussion 
This is the first randomised double-blind placebo-controlled trial to test the hypothesis that 
glutamine supplementation may have clinical benefit in individuals with CF. Although there was no 
change in the main outcome measures in the intention-to-treat analysis, the per protocol 
demonstrated that the group who received glutamine supplementation had an increase in sputum 
neutrophils, total cells and Pseudomonas Isolation Agar colony forming units after eight weeks. 
 
The strengths of these data are the randomised controlled study design that permits evaluation of 
single interventions avoiding the risk of confounding. The main outcome measures were measured 
by an individual who was not in contact with the study participant, and this can be regarded as 
another level of blinding to ensure objective endpoints. Compliance with the intervention appeared 
good, with almost all participants attending subsequent study visits to obtain further supplies of 
their allocated intervention, although there was no way of being sure that every participant 
completed every sachet of amino acid that they were given. The blinding was successful as 
demonstrated by the fact that 60% of participants were unaware of their randomisation status. The 
patients were recruited from busy cystic fibrosis centres and covered a range from mild to severe 
clinical disease, making these data generalisable to other comparable centres. 92% of patients 
completed the study suggesting that the intervention was generally acceptable to these 
individuals.  
 
There are a number of limitations that require consideration. The per protocol analysis involved a 
number of outcome measures, so the significant changes could be a consequence of multiple 
hypothesis testing, and not a true biological effect and the results should be considered 
hypothesis generating rather than definitive. The baseline Pseudomonas Isolation Agar colony 
forming units in the patients allocated to placebo were higher than those allocated to glutamine 
supplementation, and the increase in this outcome measure may represent regression to the 
mean. The choice of pulmonary inflammatory markers as the main outcome measures for this 
clinical trial was a necessary compromise to permit an evaluation of the potential of glutamine 
supplementation with CF as they are considered to be biomarkers of surrogate clinical response to 
anti-microbial interventions 15. Other outcome measures such as time to next pulmonary 
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exacerbation, a longer intervention or an intervention in a different population with CF such as 
children may provide better indications of the potential clinical benefits of glutamine in cystic 
fibrosis. Another possibility is that a biochemical measure of systemic inflammation such as C-
reactive protein may have provided a more sensitive outcome measure. We did not have the 
ability to measure objective measures of adherence, such as intra-neutrophil glutamine levels, or 
in the sputum generally and hence have no confirmation that all the glutamine supplements were 
taken as prescribed, or taken but not absorbed. As the main outcome measure was sputum 
inflammatory markers, we were unable to also measure the impact of glutamine on lean muscle 
mass, or protein or energy intake. The study was designed in response to the observation that 
other patient groups appeared to benefit from glutamine supplementation, particularly those who 
were in the critical care setting 4,5 and patients with burns 7,8. However, patients with cystic fibrosis 
have a chronic disease that is associated with malnutrition, and hence may not respond to 
glutamine supplementation in the same manner, as populations with acute disease and no 
diagnosis of CF. Finally, only 25% of those individuals who were eligible entered the study, with 
many citing time limitations as the reason for their not participating. 
 
The main outcome of our study is that there was no change in markers of pulmonary inflammation 
in the intention-to-treat analysis, although we did observe that pulmonary neutrophils and total cell 
counts increased significantly in the glutamine supplementation group compared to those who 
received placebo in the per protocol analysis. The clinical significance of this is unclear, as an 
increased inflammatory response may be beneficial in some acute situations but potentially 
detrimental if this results in chronic inflammatory response in the lungs. It is unclear if this is a true 
biological effect or a chance finding as a consequence of the many statistical analyses on these 
data. Glutamine has been demonstrated in a recent meta-analysis of studies 5 to have a possible 
clinical benefit with no clear biological mechanism, and one possibility is that glutamine results in 
stimulation of the cellular immune response, mobilising a more effective challenge to the presence 
of pathogens. However, a recent large multicenter randomised controlled trial of glutamine in 
critical care patients demonstrated no clinical benefit or reduction in secondary infections 20, and 
an association with increased mortality at six months. This study was in a very different patient 
group to CF, and gave much higher doses of glutamine than we used in our study, so direct 
comparisons with our data are impossible. The only prior study of glutamine in the context of CF 
was alongside human growth hormone in nine children and did not report any protein gain over 
four weeks 21. 
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In summary, there was no change in the primary outcome measures after glutamine 
supplementation in the intention-to-treat analysis, and as a consequence, these data suggest that 
glutamine has no clear clinical benefits in patients with cystic fibrosis. 
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Table 1. Baseline characteristics of study population 
 
 All (N=39) Glutamine (N=18) Placebo (N=21) 
Clinical measurements 
Mean Age, years (sd) 30 (10) 32 (9) 28 (9) 
Number of Males (%) 24 (62) 10 (56) 14 (67) 
Δ508 Genotype 
Homozygote 
Heterozygote 
Other 
 
26 (67) 
10 (25) 
3 (8) 
 
12 (67) 
4 (22) 
2 (11) 
 
14 (67) 
6 (29) 
1 (5) 
Mean weight, Kg (sd) 61.9 (10.8) 60.7 (7.8) 62.9 (13.0) 
Mean height, m (sd) 1.69 (0.07) 1.69 (0.07) 1.68 (0.08) 
Mean BMI, kg/m2 (sd) 21.6 (3.1) 21.1 (2.0) 22.1 (3.8) 
Mean FEV1, L (sd) 1.71 (0.64) 1.46 (0.33) 1.92 (0.76) 
Mean percent 
predicted FEV1 (sd) 
47 (16) 41 (9) 53 (20) 
Mean FVC, L (sd) 3.08 (0.84) 2.83 (0.72) 3.30 (0.89) 
Mean FEV1/FVC (sd) 66.6 (12.4) 64.1 (11.3) 68.8 (13.1) 
Mean PEF, L/min (sd) 339 (102) 316 (70) 358 (122) 
Median Clinical Score 
(IQR) 
4 (2 to 5) 
(N=37) 
4.5 (3 to 6) 
(N=18) 
3 (2 to 5) 
(N=19) 
Median induced sputum measurements (IQR) 
Neutrophils (per ml  
x 106) 
2.3 (1.3 to 3.7) 
(N=34) 
2.8 (1.8 to 4.5) 
(N=16) 
2.0 (0.9 to 2.8) 
(N=18) 
Total cells (per ml 
x 106) 
2.5 (1.3 to 3.9) 
(N=35) 
2.9 (1.9 to 4.6) 
(N=16) 
2.3 (0.9 to 3.8) 
(N=19) 
Blood agar CFU 
(x107) 
3.0 (1.5 to 15.6) 
(N=34) 
3.0 (1.1 to 1.7) 
(N=15) 
3.6 (2.0 to 1.6) 
(N=19) 
PIA CFU (x106) 6.7 (2.1 to 34.8) 
(N=35) 
4.1 (1.2 to 8.8) 
(N=16) 
23 (3 to 54) 
(N=19) 
TNFα (pg/ml) 5.6 (1.8 to 31.3) 
(N=36) 
6.3 (1.8 to 17.0) 
(N=16) 
5.3 (1.9 to 39.4) 
(N=20) 
IL1-β (pg/ml) 126 (56 to 211) 
(N=35) 
126 (57 to 211) 
(N=17) 
130 (29 to 203) 
(N=18) 
IL-6 (pg/ml) 2.7 (0.8 to 12.3) 
(N=19) 
1.1 (0.4 to 2.4) 
(N=8) 
9.0 (1.7 to 40.0) 
(N=11) 
IL-8 (pg/ml) 345 (266 to 489) 
(N=36) 
349 (286 to 461) 
(N=17) 
285 (210 to 500) 
(N=19) 
BMI = body mass index 
FEV1 = Forced expiratory volume in one second 
FVC = Forced vital capacity 
PEF = Peak expiratory flow 
IQR = interquartile range 
CFU = colony forming units 
PIA = Pseudomonas isolation agar 
TNFα = Tumour necrosis factor alpha 
IL1-β = Interleukin 1 beta 
IL6 = Interleukin 6 
IL8 = Interleukin 8 
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Table 2. Per protocol analysis of change in outcome measures for all participants who 
completed the study 
 
 Glutamine group 
(N=16) 
Placebo 
(N=20) 
Mean difference of glutamine 
compared to placebo 
Mean change in clinical measurements 
Weight, Kg +0.71 +0.45 +0.26 (-1.04 to +1.56) 
FEV1, ml +81 +26 +55 (-94 to +205) 
FVC, ml +174 +76 +97 (-175 to +370) 
Clinical Score +0.6 
(N=16) 
+0.5 
(N=17) 
+0.1 (-2.2 to +2.4) 
Median change in induced sputum measurements 
   p value 
Neutrophils (per ml x 
106) 
+3.63 
(N=10) 
+0.07 
(N=15) 
0.046 
Total cells (per ml x 
106) 
+3.8 
(N=10) 
-0.02 
(N=16) 
0.03 
Blood agar CFU 
(x107) 
0.00 
(N=11) 
+1.0 
(N=15) 
0.74 
PIA CFU (x107) +12.3 
(N=9) 
-5.2 
(N=14) 
0.04 
TNFα (pg/ml) -0.96 
(N=12) 
+0.08 
(N=14) 
0.96 
IL1-β (pg/ml) -33 
(N=15) 
-18 
(N=15) 
0.76 
IL-6 (pg/ml) -1.6 
(N=3) 
-2.5 
(N=5) 
0.88 
IL-8 (pg/ml) +132 
(N=14) 
+17 
(N=15) 
0.08 
Statistical comparisons used unpaired t-test for clinical measurements and Mann-Whitney test for 
induced sputum measurements 
FEV1 = Forced expiratory volume in one second 
FVC = Forced vital capacity 
PEF = Peak expiratory flow 
CFU = colony forming units 
PIA = Pseudomonas isolation agar 
TNFα = Tumour necrosis factor alpha 
IL1-β = Interleukin 1 beta 
IL6 = Interleukin 6 
IL8 = Interleukin 8 
 
 
 
 
 
 
 
 
 
 12 
 
 
 
 
 
 
 
Figure 1. Flow diagram of patient screening and participation on the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
